PMS2-associated Lynch syndrome: Past, present and future
Frontiers in Oncology · 21.02.2023 · 13
DOI: 10.3389/fonc.2023.1127329 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 21.02.2023. Verfasst von Katarina D Andini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding.
Abstract (Originalsprache)
Carriers of any pathogenic variant in one of the MMR genes ( path_MMR carriers) were traditionally thought to be at comparable risk of developing a range of different malignancies, foremost colorectal cancer (CRC) and endometrial cancer. However, it is now widely accepted that their cancer risk and cancer spectrum range notably depending on which MMR gene is affected. Moreover, there is increasing evidence that the MMR gene affected also influences the molecular pathogenesis of Lynch syndrome CRC. Although substantial progress has been made over the past decade in understanding these differences, many questions remain unanswered, especially pertaining to path _ PMS2 carriers. Recent findings show that, while the cancer risk is relatively low, PMS2-deficient CRCs tend to show more aggressive behaviour and have a worse prognosis than other MMR-deficient CRCs. This, together with lower intratumoral immune infiltration, suggests that PMS2-deficient CRCs might have more in common biologically with sporadic MMR-proficient CRCs than with other MMR-deficient CRCs. These findings could have important consequences for surveillance, chemoprevention and therapeutic strategies (e.g. vaccines). In this review we discuss the current knowledge, current (clinical) challenges and knowledge gaps that should be targeted by future studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, Netherlands.
- Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- Department of Applied Tumour Biology, Institute of Pathology, Heidelberg University Hospital, and Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center, Heidelberg, Germany.
- Department of Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Förderung
- KWF Kankerbestrijding
Zitieren
APA
Andini, K. D., Nielsen, M., Suerink, M., Helderman, N. C., Koornstra, J. J., Ahadova, A., Kloor, M., Mourits, M. J. E., Kok, K., Sijmons, R. H., & Bajwa-Ten Broeke, S. W. (2023). PMS2-associated Lynch syndrome: Past, present and future. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1127329
Vancouver
Andini KD, Nielsen M, Suerink M, Helderman NC, Koornstra JJ, Ahadova A, et al. PMS2-associated Lynch syndrome: Past, present and future. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1127329
BibTeX
@article{Andini2023,
author = {Andini, Katarina D and Nielsen, Maartje and Suerink, Manon and Helderman, Noah C and Koornstra, Jan Jacob and Ahadova, Aysel and Kloor, Matthias and Mourits, Marian J E and Kok, Klaas and Sijmons, Rolf H and Bajwa-Ten Broeke, Sanne W},
title = {PMS2-associated Lynch syndrome: Past, present and future},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1127329}
}
EUVIMED